ArticleBMC cancer2020
Clinical impact of PSMA PET/CT in primary prostate cancer compared to conventional nodal and distant staging: a retrospective single center study.
Article in BMC cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 54 citations in OpenAlex.
- Automated lesion tracking and treatment response classification on [European journal of nuclear medicine and molecular imaging · 2026Article
- Impact of PSMA PET Staging on Initial Treatment in Newly Diagnosed Prostate Cancer.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025Article
- Low- and High-Volume Disease in Metastatic Hormone-Sensitive Prostate Cancer: From CHAARTED to PSMA PET-An International Multicenter Retrospective Study.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025Article
- The role of the radiologist in the prostate cancer multidisciplinary conference.Abdominal radiology (New York) · 2024Review
- Comparative Performance ofDiagnostics (Basel, Switzerland) · 2024Article
- Pelvic lymph node mapping in prostate cancer: examining the impact of PSMA PET/CT on radiotherapy decision-making in patients with node-positive disease.Cancer imaging : the official publication of the International Cancer Imaging Society · 2024Article
- To see clear is not enough; it is the action that counts.Translational andrology and urology · 2024Article
- 7-[Journal of medicinal chemistry · 2023Article
- Impact of Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography on the Therapeutic Decision of Prostate Carcinoma Primary Staging: A Retrospective Analysis at the Brazilian National Public Health System.Annals of surgical oncology · 2023Article
- Dose outside of the prostate is associated with improved outcomes for high-risk prostate cancer patients treated with brachytherapy boost.Frontiers in oncology · 2023Article
- Article
- The Utility of 68Ga-PSMA PET/CT in Decisions Regarding Administering Salvage Radiotherapy to Men with Prostate Cancer.International journal of environmental research and public health · 2022Article
- Necessity of Pelvic Lymph Node Irradiation in Patients with Recurrent Prostate Cancer after Radical Prostatectomy in the PSMA PET/CT Era: A Narrative Review.Biomedicines · 2022Review
- PSMA PET-CT in the Diagnosis and Staging of Prostate Cancer.Diagnostics (Basel, Switzerland) · 2022Review
- Role of Prostate-Specific Membrane Antigen PET in Metastatic Prostate Cancer: We Have the Answers.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2022Article
- StagingEuropean journal of nuclear medicine and molecular imaging · 2022Article
- Predictive and prognostic potential of pretreatmentFrontiers in oncology · 2022Article
- Focal unspecific bone uptake on [European journal of nuclear medicine and molecular imaging · 2021Article
- Review
- Estimating the Potential of Radiomics Features and Radiomics Signature from Pretherapeutic PSMA-PET-CT Scans and Clinical Data for Prediction of Overall Survival When Treated withDiagnostics (Basel, Switzerland) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo evaluate the impact of Gallium-68 [
methodsMen with newly diagnosed biopsy-proven PCa who had been staged with a conventional staging protocol including bone scintigraphy (BS) and additionally underwent [
resultsSixty-four men with intermediate and high-risk PCa were evaluated. With additional information of PET/CT, N status was upstaged in 23%, and downstaged in 9%. M status was upstaged in 13%, and downstaged in 23%. A net increase in LoC of 20% was noted, mainly regarding M status. Treatment category changed from palliative to curative in 9%, and from curative to palliative in 3%. An undecided treatment plan changed to curative in 14%, as well as to palliative in another 9%. In total, a 36% treatment category change was noted. High negative predictive value of PET/CT for M status was indicated by 27 patients that underwent robot-assisted radical prostatectomy and reached postoperative biochemical disease-free status or had a likely other site of disease recurrence.
conclusionsPSMA PET/CT can cause considerable changes in N and M staging, as well as in management compared to conventional staging. Findings of this study support the replacement of BS and CT by PSMA PET/CT in staging primary PCa.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.